LOBESUG TABLETS
MRP: 980
Packaging: 10 x 10
Pack Type: tablet
Composition:
lobeglitazone 0.5mg
Indication:
helps improve glycemic control in adults by increasing insulin sensitivity and enhancing glucose utilization in peripheral tissues. This medication is typically used as monotherapy or in combination with other antidiabetic agents, along with diet and exercise, to achieve optimal blood sugar control.
Description:
Lobeglitazone 0.5mg is an oral antidiabetic medication used in the treatment of type 2 diabetes mellitus. It belongs to the class of thiazolidinediones (TZDs), which work by improving insulin sensitivity in peripheral tissues such as skeletal muscle, adipose tissue, and the liver. This enhances glucose uptake and reduces insulin resistance, a key factor in type 2 diabetes.
Lobeglitazone offers comparable glycemic control with a lower dose and fewer side effects compared to older TZDs. It is often used as monotherapy or in combination with metformin, sulfonylureas, or DPP-4 inhibitors for better blood sugar management.
Its once-daily dosing and improved safety profile make it a convenient and effective option for long-term diabetes control.
Tags:
- Enhances insulin sensitivity in muscle, fat, and liver cells
- Reduces insulin resistance, a key cause of type 2 diabetes
- Convenient once-daily oral dosing
- Lower dose requirement with fewer side effects compared to older TZDs
- Can be safely combined with other oral antidiabetic agents
Usage Information
Dosage
Usual Dose: 0.5mg once daily, with or without food. Do not exceed the prescribed dose. Regular blood sugar monitoring is advised. Dose adjustment may be needed based on response or in case of combination therapy.
Side Effects
Common side effects: Weight gain Mild edema (fluid retention) Headache Upper respiratory tract infections Less common but serious side effects: Heart failure in predisposed patients Liver enzyme elevation Macular edema (eye-related)
Contraindications
Type 1 diabetes mellitus Severe heart failure (NYHA Class III or IV) Active liver disease History of bladder cancer Hypersensitivity to Lobeglitazone or any excipient